Biomarker Workshop

The NMI is hosting a Protein Biomarker Workshop together with the GBM Bioanalytics Study Group and SIGNATOPE.

The event brings together leading international scientists from academic research, the pharmaceutical industry, and clinical practice. The focus is on current developments in protein biomarker research, particularly innovative technologies such as ultrasensitive immunoassays, multiplex affinity platforms, and mass spectrometric methods for quantitative protein analysis.

In addition to technological aspects, the conference will also address regulatory requirements and strategies for the successful translation of biomarkers into clinical trials. Application examples range from drug-induced organ damage and therapy monitoring to concepts in personalized medicine.

The workshop lasts two half-days and begins on September 17 at around 1:00 p.m. It ends on September 18, also at noon.

If you have any questions about the event or about paying the registration fee by invoice, please feel free to contact jens.goepfert(at)nmi.de.

Accommodations

A block of rooms has been reserved for participants at the Hotel Fortuna (Carl-Zeiss-Straße 75, 72770 Reutlingen; approximately 2 kilometers from the NMI). This block is available on a self-booking basis at a special rate. When making a reservation (by phone or email), please quote offer number 163454.

Presentations

Prof. Dr. Christoph Borchers (Jewish General Hospital, Montreal): SysQuan: affordable absolute Quantification of the entire mouse and human proteome

Warren Glaab (Merck Sharp & Dohme, USA): Current Application of Emerging Skeletal Muscle and Liver Safety Biomarkers for Monitoring Drug-Induced Skeletal Muscle and Liver Injury in Early Clinical Trials

Prof. Dr. Chris Goldring (University of Liverpool): Biomarkers and Humanised Models for Safer Medicines

Dr. med. Klemens Ruprecht (Universität Heidelberg): Blood-Based Biomarkers in Neuroimmunology: Recent Progress and Perspectives

Dr. Ulrich Kunz (Boehringer Ingelheim): The importance of Context of Use definition for biomarker measurement in clinical trials  

Dr. Dr. med. Susanne Roth (Universitätsklinikum Tübingen): Risk prediction of Intraductal Papillary Mucinous Neoplasm based on clinical & serum markers

Prof. Dr. Jochen Schwenk (KTH Royal Institute of Technology, Stockholm): Self-Sampled Blood Proteomics Reveals Molecular Health Dynamics

Dr. Annika Nelde (Universität Tübingen): Peptide-based immunotherapy – Bench to bedside developments

Dr. Oliver Pötz (SIGNATOPE GmbH, Reutlingen): TransBioLine Wrap-Up: Advancing Translational Protein Safety Biomarkers for Drug-Induced Organ Injury

Dr. Jens Göpfert (NMI, Reutlingen): Hidden Pitfalls in Biomarker Immunoassays: Lessons from Clinical Study Implementation

Dr. Markus Templin (NMI, Reutlingen): Signaling Network Profiling for Patient Stratification and Drug Target Evaluation

Dr. Gary Friedman (Predictive Safety Testing Consortium): FDA and EMA Biomarker Qualifications as Foundations for Novel, Yet-to-be-Qualified Kidney-specific Biomarkers

Dr. Marcus Bantscheff (Roche, Basel): Pharmacoproteomics Profiling Identifies Secreted Markers of Drug Action

The registration deadline is August 31, 2026!